MedTrace Logo

Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

NCT07349693 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2026-01-20

No results posted yet for this study

Summary

This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozolomide), demonstrating potential to improve outcomes in this serious and life-threatening condition

Conditions

  • Recurrent Glioblastoma, IDH-Wildtype

Interventions

DRUG

Cerebraca wafer

Cerebraca Wafer, (75 mg (Z)-n-butylidenephthalide, (Z)-BP, Implant)

DRUG

Temozolomide (for relapsed malignant glioma)

TMZ as the standard-of-care (SOC) treatment for recurrent glioblastoma.

Sponsors & Collaborators

  • Everfront Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-01
Primary Completion
2028-12-01
Completion
2030-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07349693 on ClinicalTrials.gov